Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Analysts
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average […]
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average […]
